Skip to content Skip to sidebar Skip to footer

Healthcare Stocks

Race Oncology Jumps 23% as Researchers Uncover Key Mechanism Behind Lead Cancer Drug

Race Oncology Soars 23% on Breakthrough Discovery Targeting MYC Race Oncology (ASX: RAC) opened strongly, rising 23 percent after releasing new insights into how its lead cancer drug, bisantrene (RC220 Bisantrene, RCDS1), actually works inside the body. The company’s researchers found that the drug attaches to and stabilises DNA and RNA structures known as…

ByCharlie YouldenOctober 2, 2025

EBR Systems (ASX:EBR): Another heart-focused medtech that has gained FDA approval

Mere days after Artrya (ASX:AYA) obtained FDA approval for its heart-health technology, EBR Systems (ASX:EBR) has achieved that same feat. The company made a surprising 15% plunge on the day of the announcement, and the share price has been nuanced since. However, it is still a >$500m company more than when it first listed. Let's take…

ByNick SundichOctober 1, 2025

Proteomics has launched 2 Promarker tests in a matter on months and is about to launch a 3rd

Proteomics' suite of Promarker tests are all being launched in 2025. The range includes: PromarkerD for DKD which has been launched in Australia and the USA; PromarkerEso for Esophageal cancer which is now commercially available in Australia, and PromarkerEndo for Endometriosis which will be commercialised shortly. Launching 3 tests in a a year is…

ByNick SundichSeptember 26, 2025

Amplia Therapeutics (ASX:ATX): Battling pancreatic cancer with an FAK inhibitor

Amplia Therapeutics (ASX:ATX) is another ASX oncology biotech company, attempting to battle cancer. At first glance, it may not a unique company but when you dig deeper...it is. It is using an 'FAK inhibitor' to fight pancreatic cancer (and potentially other indications down the track). What are the Best ASX Stocks to invest in right now?…

ByNick SundichSeptember 23, 2025

Starpharma (ASX: SPL) Soars 70% on Genentech Deal

Starpharma Lands Genentech Collaboration Starpharma (ASX: SPL) has caught investor attention with a stunning 70 percent share price surge after unveiling a collaboration with global biotech giant Genentech. At the heart of the deal is Starpharma’s DEP platform, which uses dendrimers—tiny, tree-like molecules designed to carry cancer drugs more effectively through the body. By “loading”…

ByCharlie YouldenSeptember 22, 2025

Nexsen: Another ‘point of care diagnostics’ company is about to hit the ASX

There's another company about to join the cohort of ASX biotech stocks and its name is Nexsen. Nexsen is proposed to list on Tuesday October 7, raising $6m at 20c per share, and to have the code NXN. This company has a rapid sensing technology that it will first commercialise to detect Group B Streptococcus…

ByNick SundichSeptember 19, 2025

Imagion Biosystems (ASX:IBX) gets ready for Phase 2

It's taken a while to get here, but the US medical device company Imagion Biosystems (ASX: IBX), which listed on the ASX way back in June 2017, is now getting to a really interesting stage of its clinical development, and has just raised $3.5m at 1.5 cents per share to fund this stage. Imagion Biosystems was…

ByNick SundichSeptember 11, 2025

Emyria’s (ASX:EMD) commercial breakthrough in psychedelic medicine

When Perth-based Emyria (ASX:EMD) announced on 18 June that Medibank would be funding eligible customer participation in Emyria's Post-Traumatic Stress Disorder care programme, with no out-of-pocket costs, investors who know the Life Sciences sector needed to sit up and take notice. Here was Australia's largest health insurer, with over 4.2 million customers, saying that it…

ByStuart RobertsSeptember 10, 2025

Artrya (ASX:AYA): With FDA 510(k) approval and $75m in fresh capital, its all systems go!

4 years after listing and over 7 years after its founding, Artrya (ASX:AYA) achieved the aspiration of most ASX medtechs, in obtaining FDA approval. Its Salix suite of products aims to improve the detection and treatment of Coronary Artery Disease (CAD), which is a major cause of heart attacks. Entering the US was always this company's…

ByNick SundichSeptember 10, 2025

Telix Pharmaceuticals (ASX:TLX) Gets FDA Green Light to Resubmit — What Investors Should Know

Telix Pharmaceuticals Gains FDA Clarity on Glioma Imaging Agent Telix Pharmaceuticals (ASX: TLX) has given investors reason to sit up and take notice. The company announced it has reached agreement with the U.S. Food and Drug Administration on the resubmission of its new drug application for TLX101-CDx (Pixclara), an imaging agent designed for glioma. What…

ByCharlie YouldenSeptember 9, 2025

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Race Oncology Jumps 23% as Researchers Uncover Key Mechanism Behind Lead Cancer Drug

EBR Systems (ASX:EBR): Another heart-focused medtech that has gained FDA approval

Proteomics has launched 2 Promarker tests in a matter on months and is about to launch a 3rd

Amplia Therapeutics (ASX:ATX): Battling pancreatic cancer with an FAK inhibitor

Starpharma (ASX: SPL) Soars 70% on Genentech Deal

Nexsen: Another ‘point of care diagnostics’ company is about to hit the ASX

Imagion Biosystems (ASX:IBX) gets ready for Phase 2

Emyria’s (ASX:EMD) commercial breakthrough in psychedelic medicine

Artrya (ASX:AYA): With FDA 510(k) approval and $75m in fresh capital, its all systems go!

Telix Pharmaceuticals (ASX:TLX) Gets FDA Green Light to Resubmit — What Investors Should Know

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Add Your Heading Text Here